ProText Mobility (ProText Mobility) Debt-to-Asset : 71.00 (As of Sep. 2014)

View and export this data going back to 2003. Start your Free Trial

What is ProText Mobility Debt-to-Asset?

ProText Mobility's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $1.42 Mil. ProText Mobility's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $0.00 Mil. ProText Mobility's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2014 was $0.02 Mil. ProText Mobility's debt to asset for the quarter that ended in Sep. 2014 was 71.00.

ProText Mobility Debt-to-Asset Historical Data

The historical data trend for ProText Mobility's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProText Mobility Debt-to-Asset Chart

ProText Mobility Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-Asset

Get a 7-Day Free Trial

5.25

4.11

4.51

485.67

286.60

ProText Mobility Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Debt-to-Asset	Get a 7-Day Free Trial															83.94	286.60	16.22	54.50	71.00

Competitive Comparison of ProText Mobility's Debt-to-Asset

For the Biotechnology subindustry, ProText Mobility's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProText Mobility's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProText Mobility's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ProText Mobility's Debt-to-Asset falls into.

ProText Mobility Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ProText Mobility's Debt-to-Asset for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.429	+	0.004)	/	0.005
	=	286.60

ProText Mobility's Debt-to-Asset for the quarter that ended in Sep. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.42	+	0)	/	0.02
	=	71.00

ProText Mobility (OTCPK:TXTM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ProText Mobility Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ProText Mobility's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ProText Mobility (ProText Mobility) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProText Mobility Inc (OTCPK:TXTM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

One West Las Olas Boulevard, Suite 500, Fort Lauderdale, FL, USA, 33301

Website

https://www.protxtm.com

ProText Mobility Inc is a Biotech Company developing a Hemp/CBD - Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes & technologies. Protext has engaged in the research, testing, and development of bioavailable botanical products all-natural ingredients formulated for nutraceuticals and pharmaceutical applications through proprietary live plant extraction technology.

Executives

Peter Sealey

director

37400 CENTRAL COURT, NEWARK CA 94560